DOI: 10.12890/2021_002265

Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab

Authors

  • Aasem Abu Shtaya epartment of Internal Medicine “B”, Lady Davis Carmel Medical Center, Haifa, Israel; Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel
  • Shai Cohen Department of Internal Medicine “B”, Lady Davis Carmel Medical Center, Haifa, Israel; Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel
  • Yana Kogan Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel; Pulmonology Institute and CF center, Lady Davis Carmel Medical Center, Haifa, Israel
  • Michal Shteinberg Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel; Pulmonology Institute and CF center, Lady Davis Carmel Medical Center, Haifa, Israel
  • Ori Sagol Technion – Israel Institute of Technology, The B. Rappaport Faculty of Medicine, Haifa, Israel; Department of Gastroenterology, Lady Davis Carmel Medical Center, Haifa, Israel

Aasemab@hotmail.com

Keywords

Crohn’s disease, granuloma, vedolizumab, infliximab

Abstract

Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the GI tract, which is frequently associated with extra-intestinal manifestations. Pulmonary parenchymal disease is very uncommon and usually considered to be debilitating and harder to diagnose. Pulmonary granulomas are rarely described in the literature as a complication of Crohn’s disease. Here, we present a patient with Crohn’s disease exacerbation who developed granulomatous lung disease under treatment with vedolizumab. Our case may add evidence to the emerging theory that gut-selective biologic agents could lead to upregulation of some pro-inflammatory factors leading to the evolution of pulmonary disease.

View the entire article

Downloads

References

  1. Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of Crohn’s disease. World J Gastroenterol 2014;20(1):133–141.
  2. MacDermott RP, Nash GS, Nahm MH. Antibody secretion by human intestinal mononuclear cells from normal controls and inflammatory bowel disease patients. Immunol Invest 1989;18(1–4):449–457.
  3. Bienenstock J, McDermott M, Befus D, O’Neill M. A common mucosal immunologic system involving the bronchus, breast and bowel. Adv Exp Med Biol 1978;107:53–59.
  4. Chew MT, Chak E, Matsukuma K. A rare cause of pulmonary nodules. Case Rep Gastroenterol 2016;10(3):633–639.
  5. Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, et al. Pulmonary manifestation of Crohn’s disease developed under treatment with vedolizumab. Am J Gastroenterol 2018;113(1):146–148.

Published

2021-02-19

How to Cite

1.
Abu Shtaya A, Cohen S, Kogan Y, Shteinberg M, Sagol O. Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab. EJCRIM [Internet]. 2021 Feb. 19 [cited 2026 Nov. 18];8(2). Available from: https://ojs.wedare.app/ejcrim/article/view/2265

Most read articles by the same author(s)